project id: TCGA-PRAD; case submitter id: TCGA-V1-A9Z9; source center: 23; state: released; a260 a280 ratio: 1.9; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.45; rna integrity number: 9.0; age at index: 63; days to birth: -23360; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; age at diagnosis: 23360; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to last follow up: 540.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to sample procurement: 0; initial weight: 140.0; portion submitter id: TCGA-V1-A9Z9-01A-21; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0;